---
title: "Entera Bio surges 51% on $275M private placement to fund Phase 3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293943376.md"
description: "Entera Bio jumps 51% after announcing a $275M oversubscribed private placement led by BVF Partners to fund EB613 Phase 3 study."
datetime: "2026-07-27T13:51:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293943376.md)
  - [en](https://longbridge.com/en/news/293943376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293943376.md)
generator: "portal-rs"
---

# Entera Bio surges 51% on $275M private placement to fund Phase 3

Entera Bio(ENTX.US) 盘中上涨近 51%，现报**3.095**美元。

消息面上，公司宣布完成超额认购的**2.75**亿美元私募融资，发行价为每股**2.04**美元，由 BVF Partners 领投。募资所得将把现金跑道延长至**2030**年，用于资助 EB613 的三期研究。交易预计于 07/28/2026 左右完成，BVF 将获得指定两名董事会董事的权利。

### Related Stocks

- [ENTX.US](https://longbridge.com/en/quote/ENTX.US.md)

## Related News & Research

- [Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%](https://longbridge.com/en/news/295783160.md)
- [Entera Bio (NASDAQ:ENTX) Announces Earnings Results](https://longbridge.com/en/news/295289580.md)
- [Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk](https://longbridge.com/en/news/294234662.md)
- [Entera Bio Q2 FY26 net loss widens to $7.3 million; R&D expenses more than double to $3.2 million](https://longbridge.com/en/news/295272747.md)
- [Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients](https://longbridge.com/en/news/294825410.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**